Lupin and Boehringer Ingelheim team up to sell diabetes drug in India
Indian pharma company Lupin (BSE: 500257) and German family-owned drugmaker Boehringer Ingelheim are to forge a joint strategic alliance for co-marketing linagliptin in India.
Boehringer Ingelheim has a strong presence in trhe DPP-4 inhibitor market, of which linagliptin is one, in India. Lupin will market and sell linagliptin under the brand name Ondero for the monotherapy and Ondero Met for the fixed-dose combination with metformin, which will be promoted by Lupin’s dedicated diabetes specialty field force. Boehringer Ingelheim will continue to sell its linagliptin and metformin combination as Trajenta and TrajentaDuo, respectively, through its own sales force and network.
Lupin’s anti-diabetic portfolio contributes 15% to Lupin’s India formulations sales. Lupin is the fourth largest company in the anti-diabetes segment and currently has 6.44% market share of the overall diabetes market, according to IMS figures quoted by Lupin.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze